Ananda is a clinical-stage biotech developing immunotherapies to reverse autoimmunity, harnessing regulatory T cells (Tregs) to restore immune tolerance and a healthy balance to the immune system. Ananda’s first-in-class platform targets a feedback loop of autoimmune inflammation, which is shared among multiple autoimmune diseases. Our approach departs dramatically from immunosuppression and is focused on an oral, peptide-based approach to induce a highly effective subset of Tregs to down-regulate autoimmune inflammation, while maintaining immune competency. Planning is underway for a Phase 2 clinical trial in Europe on our most advanced candidate, AI-005, on the basis of strong supporting clinical data on safety and efficacy from earlier trials.